Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2022 17:30 ET | Source: Celsion CORP

Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock

LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...
January 10, 2022 20:45 ET | Source: Celsion CORP

Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock

LAWRENCEVILLE, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...
November 29, 2021 08:30 ET | Source: Celsion CORP

Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit

Celsion Corporation’s GEN-1 IL-12 Program in Advanced Ovarian Cancer to be Featured in Poster Presentation Chief Science Officer Dr. Khursheed Anwer to Present and Participate in Two Panel...
November 15, 2021 08:30 ET | Source: Celsion CORP

Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update

Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE...
November 09, 2021 09:00 ET | Source: Celsion CORP

Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021

LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
November 08, 2021 09:00 ET | Source: Celsion CORP

Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses

Application Approval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, Celsion has raised...
November 08, 2021 08:30 ET | Source: Celsion CORP

Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit

Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
October 15, 2021 09:00 ET | Source: Celsion CORP

Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation Monday, October 18 at 7:30 a.m. Eastern Time LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
October 12, 2021 09:00 ET | Source: Celsion CORP

Celsion Corporation Announces Oral Presentation at International Vaccines Congress

Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation on Celsion’s Ongoing Work with DNA-based Vaccines LAWRENCEVILLE, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Celsion...
October 11, 2021 09:00 ET | Source: Celsion CORP

Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews

Investigator-Sponsored Research with ThermoDox® Continues in Multiple Indications New Support for ThermoDox®’s Potential from the National Institutes of Health under a Cooperative Research and...